A phase I/II study of SDZ PSC 833 (PSC) in combination with daunorubicin (D) and cytarabine in refractory acute myelogenous leukemia (AML).

被引：0

作者：

Liliemark, J

Bjorkholm, M

Uden, AM

Hast, R

Paul, C

Simonsson, B

Tidefelt, U

Juliusson, G

Hedenus, M

Evensen, S

Tangen, JM

Sjo, M

Nesthus, I

Hestdal, K

机构：

[1] KAROLINSKA HOSP,DEPT ONCOL,S-10401 STOCKHOLM,SWEDEN

[2] KAROLINSKA HOSP,DEPT HEMATOL,S-10401 STOCKHOLM,SWEDEN

[3] SODER SJUKHUSET,DEPT HEMATOL,STOCKHOLM,SWEDEN

[4] DANDERYD HOSP,DEPT HEMATOL,STOCKHOLM,SWEDEN

[5] HUDDINGE HOSP,DEPT HEMATOL,STOCKHOLM,SWEDEN

[6] UNIV UPPSALA HOSP,DEPT HEMATOL,UPPSALA,SWEDEN

[7] REG HOSP,DEPT HEMATOL,OREBRO,SWEDEN

[8] LINKOPING UNIV HOSP,DEPT HEMATOL,S-58185 LINKOPING,SWEDEN

[9] SUNDSVALL HOSP,DEPT HEMATOL,SUNDSVALL,SWEDEN

[10] ULLEVAL HOSP,RIKSHOSP,DEPT HEMATOL,OSLO,NORWAY

[11] REG HOSP,DEPT HEMATOL,TROMSO,NORWAY

[12] HAUKELAND HOSP,DEPT HEMATOL,N-5021 BERGEN,NORWAY

[13] SANDOZ,DEPT HEMATOL,OSLO,NORWAY

来源：

BLOOD | 1996年 / 88卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：854 / 854

页数：1

共 50 条

[1] Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
Kornblau, SM
Estey, E
Madden, T
Tron, HT
Zhao, S
Consoli, U
Snell, V
SanchezWilliams, G
Kantarjian, H
Keating, M
Newman, RA
Andreeff, M
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1796 - 1802
[2] A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
Gruber, A
Björkholm, M
Brinch, L
Evensen, S
Gustavsson, B
Hedenus, M
Juliusson, G
Löfvenberg, E
Nesthus, I
Simonsson, B
Sjo, M
Stenke, L
Tangen, JM
Tidefelt, U
Udén, AM
Paul, C
Liliemark, J
LEUKEMIA RESEARCH, 2003, 27 (04) : 323 - 328
[3] A phase I study of mitoxantrone plus VP-16 with multidrug (MDR) blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia (R-AML)
Kornblau, SM
Estey, E
Consoli, U
Zhao, S
Snell, V
Newman, R
Andreeff, M
BLOOD, 1995, 86 (10) : 2044 - 2044
[4] Daunorubicin and cytarabine compared with daunorubicin, cytarabine and the MDR1 reversal agent PSC-833 in elderly patients with acute myelogenous leukemia.
van der Holt, B
Sonneveld, P
Burnett, AK
Vossebeld, PJM
Beverloo, B
Rosenkranz, G
Dugan, M
van Putten, WLJ
Wheatley, K
Lowenberg, B
BLOOD, 2004, 104 (11) : 246A - 246A
[5] Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC-833: Results of a phase I/II multicenter study.
List, AF
Karanes, C
Dorr, R
Spier, C
Grogan, T
Greer, J
Moore, J
Weinberger, J
Schiller, G
Dalton, W
Pearce, T
Litchman, M
BLOOD, 1996, 88 (10) : 1156 - 1156
[6] A phase I dose-finding study of PSC 833, a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine (PSC-MEC) in poor prognosis acute leukemia (AML).
Visani, G
Milligan, D
Leoni, F
Chang, J
Kelsey, S
Marcus, R
Powles, R
Schey, S
Covelli, A
BLOOD, 1997, 90 (10) : 2518 - 2518
[7] Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC)
Advani, R
Saba, H
Rowe, JM
Tallman, M
Wiernik, P
Ramek, J
Dugan, K
Litchman, M
Dorr, R
Lum, B
Sikic, B
Davis, E
Paietta, E
Greenberg, P
BLOOD, 1996, 88 (10) : 847 - 847
[8] Phase I study of the chemosensitizer SDZ PSC 833 in combination with VAD chemotherapy to reverse multidrug resistance.
Dalton, W
Greipp, P
Greenberg, P
Stiff, P
Ballester, O
Friedenberg, W
Salmon, S
Kyle, R
Charnick, S
Pearce, T
BLOOD, 1996, 88 (10) : 2638 - 2638
[9] PHASE-I STUDY OF SDZ PSC833 COMBINED WITH VAD IN PATIENTS WITH REFRACTORY MULTIPLE-MYELOMA
SONNEVELD, P
MARIE, JP
GROENEWEGEN, A
BLOOD, 1994, 84 (10) : A181 - A181
[10] Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia
Dorr, R
Karanes, C
Spier, C
Grogan, T
Greer, J
Moore, J
Weinberger, B
Schiller, G
Pearce, T
Litchman, M
Dalton, W
Roe, D
List, AF
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1589 - 1599

← 1 2 3 4 5 →